Pakistan’s Pharma Industry Needs Export Reform, Says PPMA

1. PPMA Pushes for Policy Reform to Support Pharma Exports in 2025 The Pakistan Pharmaceutical Manufacturers Association (PPMA) has urged the government to bring urgent reforms that would ease the way for pharmaceutical exports in the coming year. In a press note issued this week, PPMA pointed out that while the country has strong production capacity, red tape continues to slow down growth in international markets. PPMA officials believe that Pakistani pharmaceutical companies are now producing medicines that meet international standards, but outdated export procedures are making it difficult to compete. They’ve called for faster registration systems, better access to trade events, and smoother coordination with global regulatory bodies. A Market Ready to Expand Many Pakistan pharmaceutical manufacturers have already made a mark in markets like Afghanistan, Sri Lanka, Kenya, and Nigeria. These companies, listed in the Pakistan pharmaceutical manufacturers association members list, are trying to expand their reach, but often face hurdles. “Other countries are moving faster. We have the quality and the talent — what we need now is smoother processes,” said one industry executive during a private roundtable. The concern is not just about paperwork. Companies say the current system for approvals is slow, and sometimes unpredictable. This makes it hard to build long-term trade relationships or plan ahead. Export Growth Possible — But Not Without Help According to recent trade data, Pakistan pharmaceutical exports have increased slightly over the past two years. But the rise is still small compared to what’s possible. Local pharma companies are producing tablets, syrups, and injectables that meet WHO and regional quality benchmarks. Yet they are held back by compliance challenges and weak international outreach. PPMA wants the government to set up an export support unit — a team that helps companies deal with regulations, certifications, and foreign buyer connections. This would not only boost exports, but also build Pakistan’s image as a reliable medicine source.

2. The Bigger Picture At the same time, the association made it clear that reforms should not harm local access to medicines. The idea is to strike a balance — grow exports while protecting domestic supply and affordability. With proper support, industry experts believe both goals are possible. PPMA Pakistan says it is ready to work with the Drug Regulatory Authority, the Ministry of Commerce, and international partners to move this forward. A Turning Point for Pharma The pharmaceutical industry in Pakistan has long focused on meeting local needs. Now, as global demand grows, it’s time to think bigger. With smart policies and targeted support, the sector could bring in new investment, create jobs, and open doors around the world. For now, the industry waits for a clear policy shift — one that removes roadblocks and lets local pharma companies play their part in improving global health.